Drugs indexed in China

37 drugs indexed · 5 prices independently verified. Each entry shows China approval status and price only where a source supports it.

Abemaciclib
CDK4/6
Alectinib
2nd-generation ALK-TKI
Source(s)
Last checked2026-09-08
Almonertinib
3rd-generation EGFR-TKI
Anlotinib
(TKI, )
Atezolizumab
PD-L1 inhibitor
Axicabtagene ciloleucel (CAR-T)
CD19 CAR-T cell therapy
Source(s)
Last checked2026-09-08
Bevacizumab
VEGF
Camrelizumab
PD-1 inhibitor
Dalpiciclib
CDK4/6
Disitamab vedotin (RC48)
(ADC, HER2)
Durvalumab
PD-L1 inhibitor
Source(s)
Last checked2026-09-08
Ensartinib
2nd-generation ALK-TKI
Equecabtagene Autoleucel
BCMA CAR-T cell therapy
Fluzoparib
PARP
Furmonertinib
3rd-generation EGFR-TKI
Ibrutinib
BTK
Lecheng Special Access Channel (485+ pre-NMPA drugs & devices)
Policy channel (not a single drug)
Lenvatinib
(TKI, )
Lorlatinib
3rd-generation ALK-TKI
Source(s)
Last checked2026-09-08
Niraparib
PARP
Nivolumab
PD-1 inhibitor
Source(s)
Last checked2026-09-08
Olaparib
PARP
Osimertinib
3rd-gen EGFR TKI
Palbociclib
CDK4/6
Pembrolizumab
PD-1 inhibitor
Source(s)
Last checked2026-09-08
Pertuzumab
HER2(,)
Pyrotinib
HER(TKI, )
Regorafenib
(TKI, )
Relmacabtagene autoleucel (CAR-T)
CD19 CAR-T cell therapy
Source(s)
Last checked2026-09-08
Sacituzumab govitecan
(ADC, Trop-2)
Sintilimab
PD-1 inhibitor
Source(s)
Last checked2026-09-08
Tislelizumab
PD-1 inhibitor
Toripalimab
PD-1 inhibitor
Source(s)
Last checked2026-09-08
Trastuzumab
HER2
Trastuzumab deruxtecan (T-DXd)
HER2 ADC
Venetoclax
BCL-2
Zanubrutinib
BTK